- Pfizer and BioNTech have reported early yet promising results in developing a coronavirus vaccine.
- Both NYSE:PFE and NASDAQ: BNTX are rallying in response.
- The broader stock market also received a boost in response to the promising development.
Pfizer Inc, NYSE: PFE, and BioNTech SE - ADR NASDAQ: BNTX are on the rise by tackling the most burning problem in the world – COVID-19. Scientific journal STAT reported that an initial trial held by both pharma companies was successful in creating antibodies among subjects.
The two companies tested four different vaccines among a large field of 30,000 healthy people in the US and Europe and will now continue with the next phases of trials, using the most successful solutions.
In a joint statement, Pfizer and BioNTech committed to producing a vaccine en masse – reaching over one billion in 2021.
S&P futures moved from being mixed to rising in response to the news that provides hope. It is essential to note that similar announcements by companies such as Moderna and Inovio have previously stirred markets.
Pfizer Stock Price
NYSE: PFE is trading around $34, kicking off trading on Wednesday to the upside. It previously topped $35 and remains well above Tuesday's closing price of $32.69.
The major pharmaceutical firm, based in New York, is famous for its erectile dysfunction drug but has a vast stock of medications. Gaining success – even if one shared with another firm – would solidify its position among its peers.
BioNTech comes to the COVID-19 front
BioNTech is a lesser-known company from Germany. The relatively young company was founded in 2008, at the height of the previous crisis, and trades under NASDAQ: BNTX.
Trading at BioNTech was halted after the announcement and for a good reason – BNTX shares leaped over 10% to kick off trading above the $76 price level before it eased back below $70. Nevertheless, the shares trade above the previous close levels.
Fighting coronavirus puts BioNTech in the spotlight and could allow it to grow. Other products may gain exposure.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers. The author will not be held responsible for information that is found at the end of links posted on this page.
If not otherwise explicitly mentioned in the body of the article, at the time of writing, the author has no position in any stock mentioned in this article and no business relationship with any company mentioned. The author has not received compensation for writing this article, other than from FXStreet.
FXStreet and the author do not provide personalized recommendations. The author makes no representations as to the accuracy, completeness, or suitability of this information. FXStreet and the author will not be liable for any errors, omissions or any losses, injuries or damages arising from this information and its display or use. Errors and omissions excepted.
The author and FXStreet are not registered investment advisors and nothing in this article is intended to be investment advice.
Recommended content
Editors’ Picks
AUD/USD could extend the recovery to 0.6500 and above
The enhanced risk appetite and the weakening of the Greenback enabled AUD/USD to build on the promising start to the week and trade closer to the key barrier at 0.6500 the figure ahead of key inflation figures in Australia.
EUR/USD now refocuses on the 200-day SMA
EUR/USD extended its positive momentum and rose above the 1.0700 yardstick, driven by the intense PMI-led retracement in the US Dollar as well as a prevailing risk-friendly environment in the FX universe.
Gold struggles around $2,325 despite broad US Dollar’s weakness
Gold reversed its direction and rose to the $2,320 area, erasing a large portion of its daily losses in the process. The benchmark 10-year US Treasury bond yield stays in the red below 4.6% following the weak US PMI data and supports XAU/USD.
Bitcoin price makes run for previous cycle highs as Morgan Stanley pushes BTC ETF exposure
Bitcoin (BTC) price strength continues to grow, three days after the fourth halving. Optimism continues to abound in the market as Bitcoiners envision a reclamation of previous cycle highs.
US versus the Eurozone: Inflation divergence causes monetary desynchronization
Historically there is a very close correlation between changes in US Treasury yields and German Bund yields. This is relevant at the current juncture, considering that the recent hawkish twist in the tone of the Federal Reserve might continue to push US long-term interest rates higher and put upward pressure on bond yields in the Eurozone.